Jim Cramer Notes “Merck’s Cancer Dominance Has Been Challenged of Late By JNJ”

Now Merck… Monday evening, precise odd… the existent 6:00 PM, hosts a gathering to reappraisal its crab portfolio aft the 2026 American Society of Clinical Oncology Conference. That’s the astir important crab confab of the year. Merck’s crab dominance has been challenged of precocious by JNJ. Let’s spot what Merck has to say.

Photo by Adam Nowakowski connected Unsplash

Merck & Co., Inc. (NYSE:MRK) is simply a healthcare institution that provides a wide scope of quality and veterinary pharmaceuticals, vaccines, and wellness solutions. A caller asked astir the banal during the May 1 episode, and Cramer responded:

Okay, I thought Merck got, you cognize what, Merck reported a truly bully quarter, and it conscionable happened connected a time erstwhile radical didn’t similar pharma, and they didn’t similar healthcare. And Rob Davis did a bully job. The stock’s starting to travel back. It was up $3 today. I deliberation it tin negociate its way, each the mode backmost to $120. I deliberation you bash bully homework.

While we admit the imaginable of MRK arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.